RGTP.Q Stock Overview A clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
RegenETP, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for RegenETP Historical stock prices Current Share Price US$0.11 52 Week High US$0.22 52 Week Low US$0.0026 Beta 0 1 Month Change -0.93% 3 Month Change 9.27% 1 Year Change 451.72% 3 Year Change -99.38% 5 Year Change -99.89% Change since IPO -100.00%
Recent News & Updates RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC May 21
PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers Feb 27 PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer PolarityTE, Inc. announced delayed 10-Q filing
PolarityTE, Inc. Files Form 15 Aug 12 Nasdaq to Delist the Common Stock of PolarityTE Jul 08
See more updates RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC May 21
PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers Feb 27 PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer PolarityTE, Inc. announced delayed 10-Q filing
PolarityTE, Inc. Files Form 15 Aug 12 Nasdaq to Delist the Common Stock of PolarityTE Jul 08
PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index Jun 17
New major risk - Share price stability Jun 13 PolarityTE's Common Stock To Be Delisted From Nasdaq
First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022) May 14
Full year 2022 earnings: EPS misses analyst expectations Mar 29
Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors Jan 28
Insufficient new directors Jan 19
Forecast to breakeven in 2025 Jan 03
Consensus forecasts updated Nov 17
Price target decreased to US$1.25 Nov 16
Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021) Nov 12
Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE). Nov 10
PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq Oct 31
PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors Sep 09
Consensus revenue estimates fall by 40% Aug 18
Price target decreased to US$15.38 Aug 13
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 12
PolarityTE down 10% on lower-than-expected Q2 revenue Aug 12
PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 02
Consensus forecasts updated May 23
Price target decreased to US$15.38 May 22
First quarter 2022 earnings: Revenues miss analyst expectations May 17
PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R) May 14
PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022 May 07
Price target decreased to US$1.08 Apr 27
Consensus forecasts updated Apr 06
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 31
Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely? Mar 08 PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone
PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent Feb 18
PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication Jan 19
PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application Dec 21
Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation Nov 16
Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020) Nov 12
Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc Sep 29
Independent Director Minnie Baylor-Henry has left the company Sep 07
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE® Aug 25
Consensus forecasts updated Aug 19
PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Aug 18
Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020) Aug 14
PolarityTE Is Not A DeFi Coin Jul 19
Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet? Jun 04
Independent Chairman of the Board recently bought US$259k worth of stock May 21
First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020) May 16
PolarityTE, Inc. Updates on SkinTE Biologic License Application May 15
PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint May 11
PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint May 10
PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 11
What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition Feb 19
Analysts update estimates Feb 16
PolarityTE, Inc. Announces Submission of an Investigational New Drug Application Feb 11
New 90-day high: US$1.54 Feb 10
PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial Jan 22
PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million. Jan 15
PolarityTE to raise up to $10M with at-the-market offering Jan 12
New 90-day high: US$1.32 Jan 09
PolarityTE under pressure on pricing $8M registered direct offering Dec 22
New 90-day low: US$0.63 Dec 15
PolarityTE perks up after securing first U.S. patent Nov 30
Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice Nov 25
Revenue beats expectations, earnings disappoint Nov 11
Third quarter 2020 earnings released: US$0.18 loss per share Nov 11
New 90-day low: US$0.81 Nov 10
PolarityTE EPS beats by $0.02, beats on revenue Nov 09
PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE® Nov 05
PolarityTE, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Oct 27
New 90-day low: US$1.01 Oct 19
PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds Sep 22
PolarityTE, Inc. Announces SkinTE™ Health Economics — DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure Sep 17
New 90-day low - US$1.07 Sep 04
First half earnings released Aug 07 PolarityTE, Inc.(NasdaqCM:PTE) dropped from Russell Small Cap Completeness Index Shareholder Returns RGTP.Q US Biotechs US Market 7D -2.6% -0.1% -0.5% 1Y 451.7% -6.4% 23.2%
See full shareholder returns
Return vs Market: RGTP.Q exceeded the US Market which returned 23% over the past year.
Price Volatility Is RGTP.Q's price volatile compared to industry and market? RGTP.Q volatility RGTP.Q Average Weekly Movement 26.4% Biotechs Industry Average Movement 11.1% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Stable Share Price: RGTP.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RGTP.Q's weekly volatility has decreased from 200% to 26% over the past year, but is still higher than 75% of US stocks.
About the Company RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.
Show more RegenETP, Inc. Fundamentals Summary How do RegenETP's earnings and revenue compare to its market cap? RGTP.Q fundamental statistics Market cap US$805.66k Earnings (TTM ) -US$8.30m Revenue (TTM ) US$73.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RGTP.Q income statement (TTM ) Revenue US$73.00k Cost of Revenue US$125.00k Gross Profit -US$52.00k Other Expenses US$8.25m Earnings -US$8.30m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 08:43 End of Day Share Price 2025/01/08 00:00 Earnings 2023/03/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources RegenETP, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jonathan Aschoff B. Riley Wealth Kristen Kluska Cantor Fitzgerald & Co. Joshua Schimmer Evercore ISI
Show 8 more analysts 
